Trial · NCT03936517
Safety and Efficacy of Prednisolone in Adrenal Insufficiency Disease (PRED-AID Study)
NCT03936517, Phase 3, Unknown, Imperial College London
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Safety and Efficacy of Prednisolone in Adrenal Insufficiency Disease (PRED-AID Study). Trials, record NCT03936517. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03936517
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Safety and Efficacy of Prednisolone in Adrenal Insufficiency Disease (PRED-AID Study)
- NCT number
- NCT03936517
- Status
- Unknown
- Phases
- Phase 3
- Enrollment
- 44 participants, estimated
- Lead sponsor
- Imperial College London
- Conditions
- Adrenal Insufficiency
- Interventions
- Prednisolone, Hydrocortisone
- First posted
- 2019-05-03
- Last updated
- 2023-09-01
- Other registries' IDs
- eudract:2018-001502-28, isrctn:ISRCTN41325341
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in concentration of Osteocalcin | Between Day 1 and Day 120 within each study period; and between Day 120 of Period 1 and Period 2. | Assesses bone health of each group by comparing total osteocalcin and undercarboxylated osterocalcin |
| Secondary | Change in concentration of P1NP | Between Day 1 and Day 120 within each study period; and between Day 120 of Period 1 and Period 2. | Assesses bone health of each group by comparing P1NP |
| Secondary | Change in concentration of BALP | Between Day 1 and Day 120 within each study period; and between Day 120 of Period 1 and Period 2. | Assesses bone health of each group by comparing BALP |
| Secondary | Change in concentration of NTX | Between Day 1 and Day 120 within each study period; and between Day 120 of Period 1 and Period 2. | Assesses bone health of each group by comparing NTX |
| Secondary | Heart Rate | Between Day 1 and Day 120 within each study period; and between Day 120 of Period 1 and Period 2. | recording observations- heart rate |
| Secondary | Systolic and diastolic blood pressure | Between Day 1 and Day 120 within each study period; and between Day 120 of Period 1 and Period 2. | recording observations- blood pressure |
| Secondary | Waist-Hip circumference | Between Day 1 and Day 120 within each study period; and between Day 120 of Period 1 and Period 2. | recording observations- Waist-Hip circumference ratios |
| Secondary | Change in concentration of Lipid profile (Total cholesterol, HDL, LDL and triglycerides) | Between Day 1 and Day 120 within each study period; and between Day 120 of Period 1 and Period 2. | measuring biochemical indicators of cardiovascular risk: total cholesterol, HDL, LDL and triglycerides |
| Secondary | Change in concentration of high sensitivity CRP | Between Day 1 and Day 120 within each study period; and between Day 120 of Period 1 and Period 2. | measuring biochemical indicators of cardiovascular risk: high sensitivity CRP |
| Secondary | Change in concentration of Glucose | Between Day 1 and Day 120 within each study period; and between Day 120 of Period 1 and Period 2. | measuring glucose |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 41874506 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03936517
GET https://conductscience.org/api/trials/v1/NCT03936517/registered